Overview of the ROCKstar Study

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

Now Viewing

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

EP: 10.AGAVE-201: Axatilimab for cGVHD

EP: 11.Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

EP: 12.Clinical Impact of Patient-Reported Outcomes in cGVHD

Video content above is prompted by the following:

• Dr Holtan:Please review data that led to belumosudil’s FDA approval (Jagasia M, et al. J Clin Oncol. 2021; Cutler C, et al. Blood. 2021).
  • Study design and patient demographics
  • Efficacy data (duration of effect, need for additional treatments, data on decrease in formation of scar tissue and decrease in immune cell activity, etc).
  • Safety profile of belumosudil and adverse effect management.